心力衰竭:预防和治疗缺一不可

Heart Failure:Prevention and Treatment are Indispensable

美国心脏协会、美国心脏病学会和美国心力衰竭协会联合发布了《2022年AHA/ACC/HFSA心力衰竭管理指南》。该指南倡导心力衰竭防治并重,强调基于利钠肽筛查的一级预防对A期(心力衰竭风险期)或B期(心力衰竭前期)患者至关重要;推荐C期(心力衰竭期)患者应接受多学科团队管理,尽早使用包括钠-葡萄糖协同转运蛋白2抑制剂的“基础四联疗法”;并推荐将希望延长生存期的D期(心力衰竭晚期)患者及时转诊至心力衰竭专科团队,以评估晚期心力衰竭治疗的适用性。

Recently,2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure has been published.It advocates to pay equal attention to the prevention and treatment of heart failure;and emphasizes that primary prevention based on natriuretic peptides screening is essential for patients at risk for heart failure or with pre-heart failure.Furthermore,it recommends that patients with symptomatic heart failure should receive care from a multidisciplinary team to facilitate the implementation of“basic quadruple therapy”including sodium glucose cotransporter 2 inhibitors;and that patients with advanced heart failure who wish to prolong their survival should be timely referral for heart failure specialty care and assess suitability for advanced heart failure therapies.